Cholinesterase inhibitors and Gingko extracts--are they comparable in the treatment of dementia? Comparison of published placebo-controlled efficacy studies of at least six months' duration
by
Wettstein A.
Stadtarztlicher Dienst, Zurich.
albert.wettstein@gud.stzh.ch
Phytomedicine 2000 Jan;6(6):393-401

ABSTRACT

The efficacy of four cholinesterase inhibitors (tacrine, donepezil, rivastigmine, metrifonate) and Ginkgo special extract EGb 761 in Alzheimer's disease were compared. The differences in the effects of the active substance and placebo on cognition were measured on the ADAS-Cog scale, taking into account the different degrees of dementia in the various studies and the dropout rate due to adverse drug reactions. Efficacy, expressed as the delay in symptom progression or the difference in response rate between active substance and placebo, showed no major differences between the four cholinesterase inhibitors and the Ginkgo special extract. Only tacrine exhibited a high dropout rate due to adverse drug reactions. In view of this, the subject of new prescriptions should be critically reviewed. Second-generation cholinesterase inhibitors (donepezil, rivastigmine, metrifonate) and Ginkgo special extract EGb 761 should be considered equally effective in the treatment of mild to moderate Alzheimer's dementia.

Gingko
Piracetam
Idebenone
Vinpocetine
Vasopressin
Desmopressin
Meclofenoxate
New brain cells
Ginkgo: doubts
Ginkgo biloba versus tacrine (Cognex)

Refs
HOME
HedWeb
Future Opioids
BLTC Research
SMART DRUGS 2: review
The Hedonistic Imperative
Critique of Huxley's Brave New World

The Good Drug Guide
The Responsible Parent's Guide
To Healthy Mood Boosters For All The Family